Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study
被引:22
作者:
Kataoka, K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Kataoka, K.
[1
]
Nannya, Y.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Nannya, Y.
[1
]
Ueda, K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Ueda, K.
[1
]
Kumano, K.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo 113, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Kumano, K.
[1
,2
]
Takahashi, T.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Takahashi, T.
[1
]
Kurokawa, M.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo 113, JapanUniv Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
Kurokawa, M.
[1
,2
]
机构:
[1] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan
[2] Tokyo Univ Hosp, Dept Cell Therapy & Transplantat Med, Tokyo 113, Japan
This retrospective study examined the differences in the prognostic impact of the haematopoietic cell transplantation- specific comorbidity index (HCT-CI) on transplant outcomes by disease status and time from transplant in allogeneic haematopoietic stem cell transplantation (HSCT) recipients at a Japanese transplant centre. Of 187 patients, nonrelapse mortality (NRM) at 3 years was 9.6, 21.2 and 27.8% in the low-risk (score 0), intermediate-risk (score 1-2) and high-risk (score >= 3) HCT-CI groups, respectively (P=0.03). The corresponding overall survival (OS) at 3 years was 70.1, 60.5 and 38.9%, respectively (P<0.01). In multivariate analyses, high-risk HCT-CI significantly predicted higher NRM (relative risk, (RR) 2.44 (95% confidence interval, (CI) 1.02-5.85); P=0.04) and worse OS (RR 2.02 (95% CI 1.15-3.54); P=0.01). In the subgroup analysis according to disease status, the HCT-CI was associated with OS (P<0.01) and NRM (P-0.07) in patients with low-risk diseases, but not in those with high-risk diseases. Within patients who survived without relapse >1 year after HSCT, the HCT-CI did not predict OS (P=0.59) or NRM (P-0.31). These findings can be useful to determine the role of pretransplant comorbidity in allogeneic HSCT.